Kamel-Reid S - Search Results

1

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Deininger MW, et al. Br J Haematol. 2014 Jan;164(2):223-32. doi: 10.1111/bjh.12618. Epub 2013 Nov 4. Br J Haematol. 2014. PMID: 24383843 Free PMC article. Clinical Trial.

2

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. Radich JP, et al. Blood. 2012 Nov 8;120(19):3898-905. doi: 10.1182/blood-2012-02-410688. Epub 2012 Aug 22. Blood. 2012. PMID: 22915637 Free PMC article. Clinical Trial.

3

BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.

Kim DD, Lee H, Kamel-Reid S, Lipton JH. Kim DD, et al. Br J Haematol. 2013 Mar;160(5):630-9. doi: 10.1111/bjh.12187. Epub 2012 Dec 24. Br J Haematol. 2013. PMID: 23278256 Free article.

4

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM. Storring JM, et al. Br J Haematol. 2009 Jun;146(1):76-85. doi: 10.1111/j.1365-2141.2009.07712.x. Epub 2009 May 4. Br J Haematol. 2009. PMID: 19438471 Free article. Clinical Trial.

5

Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?

Kim DH, Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH. Kim DH, et al. Am J Hematol. 2010 Nov;85(11):856-62. doi: 10.1002/ajh.21850. Am J Hematol. 2010. PMID: 20882527 Free article.

6

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.

Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. Kim DD, et al. Am J Hematol. 2014 Jun;89(6):626-32. doi: 10.1002/ajh.23707. Epub 2014 Apr 10. Am J Hematol. 2014. PMID: 24619861 Free article.

7

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.

Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: kamel reid s. Br J Haematol. 2021 May;193(4):779-791. doi: 10.1111/bjh.17447. Epub 2021 Apr 20. Br J Haematol. 2021. PMID: 33876423 Clinical Trial.

8

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.

Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B. Kim DDH, et al. Among authors: kamel reid s. Br J Haematol. 2022 Jan;196(1):136-145. doi: 10.1111/bjh.17807. Epub 2021 Sep 8. Br J Haematol. 2022. PMID: 34496035

9

Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.

Medeiros BC, Chun K, Kamel-Reid S, Lipton J. Medeiros BC, et al. Am J Hematol. 2007 Aug;82(8):758-60. doi: 10.1002/ajh.20882. Am J Hematol. 2007. PMID: 17301975 Free article.

10

No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.

Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH. Kim DH, et al. Cancer. 2008 Aug 15;113(4):772-81. doi: 10.1002/cncr.23607. Cancer. 2008. PMID: 18543309 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page